Valuation: Physiomics Plc

Market Cap 2.13M 2.88M 2.49M 2.34M 4.01M 276M 4.07M 27.49M 10.77M 138M 10.83M 10.59M 460M P/E 2026 *
-4.7x
P/E 2027 * -
Enterprise Value 1.86M 2.52M 2.18M 2.05M 3.51M 242M 3.56M 24.06M 9.43M 121M 9.48M 9.27M 403M EV / Sales 2026 *
1.86x
EV / Sales 2027 * -
Free-Float
76.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

1 week+5.62%
Current month-2.08%
1 month-10.48%
3 months-14.55%
6 months-6.00%
Current year+64.91%
1 week 0.43
Extreme 0.4265
0.48
1 month 0.41
Extreme 0.41
0.55
Current year 0.25
Extreme 0.2525
0.8
1 year 0.25
Extreme 0.2525
0.8
3 years 0.25
Extreme 0.2525
3.19
5 years 0.25
Extreme 0.2525
7.28
10 years 0.25
Extreme 0.2525
32
Manager TitleAgeSince
Director of Finance/CFO 52 -
Chief Operating Officer - 01/07/2026
Corporate Officer/Principal - 31/08/2021
Director TitleAgeSince
Director/Board Member - 29/04/2026
Chairman 53 29/04/2026
Director/Board Member - 29/04/2026
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Buy

Director

3,000,000 0.6619%
7/10/26 A Buy

Director

1,111,111 0.2452%
11/8/24 A Buy

Chief Executive Officer

459,090 0.2259%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.62%+10.59%-51.79% 2.88M
+1.83%+2.29%-24.16%+9.43% 123B
+2.13%-3.87%-42.13%-19.41% 43.76B
+2.20%+0.19%+1.28%+8.19% 40.91B
+2.85%-0.07%-25.97%-5.37% 21.36B
-1.29%-0.14%-38.53%-36.67% 18.06B
+0.08%-2.19%+2.56%+60.87% 16.29B
+0.98%-1.12%-9.99%+2.87% 15.23B
+3.13%+0.87%-23.10%-33.53% 10.15B
+4.49%+2.42%+38.90%+57.99% 4.07B
Average +1.64%-0.50%-11.06%-0.74% 29.31B
Weighted average by Cap. +1.75%-0.51%-21.18%+2.74%

Financials

2026 *2027 *
Net sales 1M 1.35M 1.17M 1.1M 1.88M 130M 1.91M 12.91M 5.06M 64.88M 5.08M 4.97M 216M -
Net income -314K -425K -367K -345K -591K -40.73M -599K -4.05M -1.59M -20.37M -1.6M -1.56M -67.86M -
Net Debt -266K -360K -311K -293K -500K -34.51M -508K -3.43M -1.35M -17.26M -1.35M -1.32M -57.49M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
10
Date Price Change Volume
19/08/26 GBX 0.4700 0.00% 0
18/08/26 GBX 0.4700 +4.44% 11,256,678
17/08/26 GBX 0.4500 0.00% 2,483,303
14/08/26 GBX 0.4500 +1.12% 1,325,705
13/08/26 GBX 0.4450 0.00% 82,327

Annual profits - Rate of surprise